Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 688 across all filing types
Latest filing 2021-09-10 Earnings Release
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Inventiva’s 2021 First-Half Financial Results Presentation
Earnings Release Classification · 98% confidence The document is titled 'Inventiva's 2021 First-Half Financial Results Presentation' and explicitly states that management will host a webcast to present the 'first-half financial results for 2021' on a specific date. It also details the exact time the financial results will be released and schedules a subsequent conference call with Q&A. This structure—announcing the release of period-specific financial results followed by a call to discuss them—is characteristic of an Earnings Release (ER). Although it mentions a 'Presentation' in the title, the primary function described is the announcement of the financial results release and the subsequent call, not the presentation itself or the full interim report. It is not an Interim/Quarterly Report (IR) because it is an announcement *about* the results release and call, not the comprehensive report itself. It is also not a Call Transcript (CT) as it is the announcement *before* the call. It is most accurately classified as an Earnings Release (ER) as it focuses on the announcement of the period's financial performance highlights and the associated call details. H1 2021
2021-09-10 English
Inventiva announces the initiation of its pivotal Phase III clinical trial evaluating lanifibranor in NASH
Regulatory Filings Classification · 95% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (PRESS RELEASE) and announces the initiation of a pivotal Phase III clinical trial for a drug candidate (lanifibranor). It provides key highlights, quotes from management and investigators, and details about the trial structure (NATiV3). This format—a concise announcement of a significant corporate/clinical event—is characteristic of an Earnings Release (ER) or a general press release. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV, the most appropriate classification for a press release announcing major operational/clinical news is 'Earnings Release' (ER), as this category often encompasses major operational announcements outside of routine financial reporting, or 'Regulatory Filings' (RNS) as a fallback. Given the focus on clinical trial initiation and future results expectations, ER is a strong fit for a major operational update announced via press release. However, since the content is purely clinical/operational news and not financial results (which ER usually implies), and it is a press release, it fits well under the general 'Regulatory Filings' (RNS) category if ER is strictly reserved for financial results. Given the options, and recognizing that press releases announcing major operational milestones often fall into the general announcement category, RNS is the safest general classification, but ER is often used for major operational updates announced via press release. Let's re-evaluate based on the definitions. ER is 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is not financial results. Therefore, RNS ('General regulatory announcements and fallback category') is the most suitable classification for a clinical trial initiation press release that doesn't fit other specific categories like LTR or CAP.
2021-09-08 English
Inventiva annonce le lancement de l’étude clinique pivot de Phase III évaluant lanifibranor dans la NASH
Regulatory Filings Classification · 90% confidence The document is titled "COMMUNIQUE DE PRESSE" and "PRESS RELEASE" and announces the launch of a Phase III clinical study (NATiV3) for a drug called lanifibranor. It details the study design, endpoints, expected timelines for results (S2 2024), and quotes key personnel. This type of announcement, focusing on a significant operational/clinical development milestone rather than routine financial results (like 10-K or ER) or a formal regulatory filing, is best classified as an Investor Presentation (IP) if it were a deck, or more generally, a press release detailing corporate/clinical progress. Since the document is a detailed press release announcing a major clinical trial initiation and providing extensive background on the drug and disease, it functions as key information disseminated to investors. Given the options, it is not a formal regulatory filing (10-K, AR, MRQ), nor is it a transcript (CT) or a simple dividend notice (DIV). It is a detailed update on corporate/clinical progress. While it could potentially fall under RNS (Regulatory Filings) as a general announcement, the content is highly specific to clinical development and strategy, making it very similar to an Investor Presentation (IP) in function, though formatted as a press release. However, press releases announcing clinical trial milestones are often categorized under general corporate updates. Given the comprehensive nature detailing the trial, mechanism of action, and regulatory strategy (accelerated approval), it is a significant communication to investors. Since there is no specific 'Press Release' or 'Clinical Update' code, and it is not a formal financial report, the closest fit that captures detailed corporate/clinical progress information intended for investors, which often accompanies or precedes formal filings, is 'Investor Presentation' (IP) or the fallback 'RNS'. Given the length and detail, it is more substantial than a typical 'RPA'. I will classify it as 'IP' as it serves the function of presenting detailed investment-relevant information about the company's pipeline progress, even if the format is a press release, or 'RNS' as a general corporate announcement. Given the context of financial reporting databases, detailed clinical updates are often grouped with investor materials. I will lean towards RNS as the most appropriate general corporate/regulatory announcement category when a specific clinical update code is missing, as this is a formal announcement of a major corporate event (launching Phase III).
2021-09-08 French
Inventiva announces the implementation of an At-The-Market program in the United States
Capital/Financing Update Classification · 98% confidence The document is a press release titled "Inventiva announces the implementation of an At-The-Market program in the United Sates." It details the establishment of an ATM program allowing the company to sell up to $100,000,000 in American Depositary Shares (ADSs) to raise capital for R&D and working capital. This activity directly relates to fundraising, financing activities, and changes in the capital structure (issuance of new shares/ADSs). This aligns perfectly with the definition of 'Capital/Financing Update' (Code: CAP). Although it mentions the authorization came from a prior AGM resolution, the primary purpose of this announcement is the financing mechanism itself, not the AGM results (DVA) or the general report publication (RPA/RNS).
2021-08-02 English
Inventiva annonce la mise en place d’un programme At-The-Market aux Etats-Unis
Capital/Financing Update Classification · 98% confidence The document is a press release dated August 2, 2021, announcing the establishment of an At-The-Market (ATM) equity financing program for up to $100 million. This action directly relates to fundraising, financing activities, and capital structure changes. The key terms are 'programme At-The-Market', 'financement en fonds propres', and 'produit net des potentielles émissions d'ADSs'. This clearly aligns with the definition of 'Capital/Financing Update' (CAP). Although it mentions the 20th resolution from the Annual General Meeting, the primary subject is the new financing mechanism, not the AGM results or the meeting itself. It is not a full 10-K, an ER, or an IR, but a specific announcement about raising capital.
2021-08-02 French
Inventiva présente ses informations financières du 1er semestre 2021
Earnings Release Classification · 99% confidence The document is titled "Inventiva présente ses informations financières du 1er semestre 2021" (Inventiva presents its financial information for the first half of 2021). It details the company's cash position as of June 30, 2021, and revenue for the first half of 2021 (S1 2021). It explicitly states that the financial information is 'non auditée' (unaudited) and provides a detailed breakdown of cash flows and operational highlights for the six-month period ending June 30, 2021. This content structure—a comprehensive financial update for a period shorter than a year, including balance sheet snapshots and income statement highlights—is characteristic of an Interim/Quarterly Report (IR). It is not merely an Earnings Release (ER) as it contains detailed cash flow analysis, nor is it the full Annual Report (10-K). It is also not an announcement of a report (RPA) because it contains the substantive financial data itself. H1 2021
2021-07-28 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.